0
Please log in or register to do it.

Alteogen

Alteogen

(Seoul = Larose.VIP) Reporter Kim Hyun-soo = Bio company Alteogen changed the license agreement it signed with global pharmaceutical company MSD in 2020, granting MSD worldwide exclusive rights to the technology for converting intravenous formulation biopharmaceuticals into subcutaneous injection formulations. It was announced on the 22nd that it would do so.

In June 2020, Alteogen announced that it had signed a non-exclusive Lions contract to transfer the source technology of human hyaluronidase enzyme (ALT-B4) to one of the top 10 global pharmaceutical companies. The contract amount was approximately 19.4 billion won, but due to trade secrets, the contract partner was not disclosed.

Following the contract change, Alteogen disclosed the contract counterparties and development items that had not previously been disclosed.

Alteogen announced that it will supply ALT-B4 to MSD to develop and commercialize a subcutaneous formulation of the cancer immunotherapy drug Keytruda (ingredient name: pembrolizumab).

Alteogen will receive an additional down payment of approximately 26.7 billion won, and upon approval and sale of MSD’s product, it will receive additional milestones (stage-based technology fees) and royalties based on net sales.

hyunsu@yna.co.kr

Report to KakaoTalk okjebo 2024/02/22 16:50 Sent

Google launches Gemma, an open product suite
Oh Se-hoon, 'folder greeting' at Boramae Hospital... “Thank you to the medical staff protecting the scene.”

Reactions

0
0
0
0
0
0
Already reacted for this post.

Reactions

Your email address will not be published. Required fields are marked *